UK markets open in 4 hours 53 minutes
  • NIKKEI 225

    29,458.40
    -725.56 (-2.40%)
     
  • HANG SENG

    24,216.94
    -283.45 (-1.16%)
     
  • CRUDE OIL

    74.43
    -0.86 (-1.14%)
     
  • GOLD FUTURES

    1,736.30
    -1.20 (-0.07%)
     
  • DOW

    34,299.99
    -569.38 (-1.63%)
     
  • BTC-GBP

    30,780.89
    -813.59 (-2.58%)
     
  • CMC Crypto 200

    1,029.17
    -27.97 (-2.65%)
     
  • ^IXIC

    14,546.68
    -423.29 (-2.83%)
     
  • ^FTAS

    4,035.41
    -32.41 (-0.80%)
     

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

COPENHAGEN, Denmark, June 10, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Henrik Birk

2.

Reason for the notification

a)

Position/status

Executive Vice President and Chief Operating Officer of Bavarian Nordic A/S

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bavarian Nordic A/S

b)

LEI

2138006JCDVYIN6INP51

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument


Identification code

Shares


DK0015998017

b)

Nature of the transaction

Exercise of warrants

c)

Price(s) and volume(s)

Price(s)

Volume(s)

DKK 205.80

12,191

d)

Aggregated information



12,191
DKK 2,508,907.80

e)

Date of the transaction

2021-06-10

f)

Place of the transaction

Nasdaq Copenhagen A/S, XCSE


1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Henrik Birk

2.

Reason for the notification

a)

Position/status

Executive Vice President and Chief Operating Officer of Bavarian Nordic A/S

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bavarian Nordic A/S

b)

LEI

2138006JCDVYIN6INP51

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument


Identification code

Shares


DK0015998017

b)

Nature of the transaction

Sale

c)

Price(s) and volume(s)

Price(s)

Volume(s)

DKK 281.67

3,349

d)

Aggregated information



3,349
DKK 943,308.90

e)

Date of the transaction

2021-06-09

f)

Place of the transaction

Nasdaq Copenhagen A/S, XCSE

About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Our commercial product portfolio furthermore contains the market-leading vaccine Rabipur®/RabAvert® against rabies and Encepur® against tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, MVABEA®, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine based on an in-licensed capsid virus-like particle technology. The vaccine candidate, ABNCoV2, is currently being investigated in clinical trials. For more information visit www.bavarian-nordic.com.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

Company Announcement no. 24 / 2021

Attachment


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting